Clinical Trials | January 11, 2026
Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India’s pharmaceutical sector stands at a pivotal inflection point
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
